


PRODUCT INFORMATION



ODM-203

Item No. 31451

CAS Registry No.: 1430723-35-5
Formal Name: N-[2',4'-difluoro-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]][1,1'-biphenyl]-3-yl]-cyclopropanesulfonamide
MF: C₂₆H₂₁F₂N₅O₂S
FW: 505.5
Purity: ≥98%
UV/Vis.: λ_{max}: 239 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

ODM-203 is supplied as a crystalline solid. A stock solution may be made by dissolving the ODM-203 in the solvent of choice, which should be purged with an inert gas. ODM-203 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of ODM-203 in these solvents is approximately 10 and 2 mg/ml, respectively.

ODM-203 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ODM-203 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. ODM-203 has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

ODM-203 is a dual inhibitor of VEGFR and FGFR (IC₅₀s = 5-26 and 6-35 nM for VEGFR1-3 and FGFR1-4, respectively).¹ It is selective for VEGFR1-3 and FGFR1-4 over a panel of 308 kinases at 1 μM, but does inhibit the receptor tyrosine kinases PDGFRα, PDGFRβ, and DDR1 (IC₅₀s = 35, 169, and 6 nM, respectively), as well as MAP4K4, MINK1, RET, SIK2, YES1, and Tie2 (IC₅₀s = 49, 41, 8, 23, 152, and 174 nM, respectively). ODM-203 inhibits FGFR-dependent proliferation in H1581 lung, SNU-16 stomach, and RT4 bladder cancer cells (IC₅₀s = 104, 132, and 192 nM, respectively) and VEGF-induced tube formation by human umbilical vein endothelial cells (HUVECs; IC₅₀ = 33 nM). *In vivo*, ODM-203 (20 and 40 mg/kg) decreases tumor volume in an RT4 mouse xenograft model. It also reduces tumor growth and intratumor phosphorylation of FGFR in a SNU-16 mouse xenograft model when administered at a dose of 30 mg/kg.

Reference

1. Holmström, T.H., Moilanen, A.-M., Ikonen, T., *et al.* ODM-203, a selective inhibitor of FGFR and VEGFR, shows strong antitumor activity, and induces antitumor immunity. *Mol. Cancer Ther.* **18**(1), 28-38 (2019).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/10/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM